Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says
Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.
You may also be interested in...
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
US FDA pilot program linking drug approval documents to sponsors' clinical study reports will improve review efficiency and access to information by medical researchers and drug developers, commissioner says; move also could aid sponsors when it comes to reimbursement decision-making, Foley and Lardner's Rosen predicts.
Contrary to previous guidance, applicants must submit as of Jan 1 all MRP submissions in eCTD format, including submissions for ongoing regulatory activities which may not have been originally submitted in this format.